Evolus Inc diskutieren
Evolus Inc
WKN: A2JDYX / Symbol: EOLS / Name: Evolus / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
10,60 €
-2,75 %
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating. They now have a $16.00 price target on the stock, up previously from $10.00.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Neueste Beiträge
HC_Wainwright in Protagonist Therapeutics Inc diskutieren